DiaMedica Therapeutics Inc. (DMAC) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 6 Buy.
The consensus price target is $8.33 (low: $7.00, high: $10.00), representing an upside of 27.4% from the current price $6.54.
Analysts estimate Earnings Per Share (EPS) of $-0.59 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.60 vs est $-0.59 (missed -1.3%). 2025: actual $-0.70 vs est $-0.68 (missed -2.3%). Analyst accuracy: 98%.
DMAC Stock — 12-Month Price Forecast
$8.33
▲ +27.37% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for DiaMedica Therapeutics Inc., the average price target is $8.33, with a high forecast of $10.00, and a low forecast of $7.00.
The average price target represents a +27.37% change from the last price of $6.54.
Highest Price Target
$10.00
Average Price Target
$8.33
Lowest Price Target
$7.00
DMAC Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to DiaMedica Therapeutics Inc. in the past 3 months
EPS Estimates — DMAC
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.60
vs Est –$0.59
▼ 1.2% off
2025
Actual –$0.70
vs Est –$0.68
▼ 2.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — DMAC
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
